Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroSync

Full company profile

uuid0007g1p

Namestring
NeuroSync
Legal namestring
NeuroSync Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NeuroSync, Inc. (formerly SyncThink) is a privately held digital health company founded in 2015 by neurosurgeon Dr. Jam Ghajar, headquartered in Holliston, Massachusetts with additional offices in Boston and a technology presence in Palo Alto. The company develops a VR-based eye tracking platform that uses proprietary algorithms — developed over more than 15 years of clinical research and protected by 16 patents — to record, analyze, and quantify eye movement patterns as objective biomarkers for neurological conditions, most notably concussion. Its flagship product, EYE-SYNC, is an FDA-cleared (510(k) 2016, Breakthrough Device Designation 2019, concussion diagnosis clearance 2021), CE Mark-certified (2022) wireless VR system that completes assessments in under 60 seconds, integrates with EMR systems via REST API, and stores data in HIPAA-compliant cloud infrastructure. PRO-SYNC, launched in 2022, extends the underlying technology into consumer brain performance and wellness monitoring via a mobile app, while the NeuroSync Management Portal (October 2023) provides a web-based administrative layer for provider workflows.

The company sells EYE-SYNC as a bundled hardware-plus-software solution (Pico Neo 3 Pro Eye VR headset, Samsung tablet, proprietary analytics software, EMR integration) under multi-year enterprise contracts with quote-based pricing, supplemented by provider training and certification, clinical trial services for CNS drug development, and recurring software/cloud subscription. Go-to-market is enterprise field sales targeting four primary verticals: healthcare providers (hospitals and clinics such as Massachusetts General Hospital, Texas Medical Center, Houston Methodist, Sutter Health, and Barnabas Health), collegiate and professional sports organizations (Rice University, Georgia Tech, Virginia Tech), military and Department of Defense buyers, and biopharma companies running CNS clinical trials. The platform has been deployed to 5,188 clinicians and used for 405,000 patient assessments, generating a proprietary dataset of over 1.57 billion data points. Distribution is enabled through hardware partnerships with Pico Interactive and Tobii, with an expanding relationship with Magic Leap for future AR-based product development. The company is led by Chairman, CEO and President Gary L. Gregory, who has led multiple healthcare startups including an IPO at NeuroMetrix. In May 2025, the FDA's Center for Devices and Radiological Health issued a warning letter to NeuroSync for design control failures on the EYE-SYNC device.

Short descriptiontext

NeuroSync develops an FDA-cleared, VR-based eye tracking platform that uses proprietary algorithms to assess brain health and diagnose concussion, serving healthcare providers, sports organizations, military, and biopharma customers across the US and EU.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHolliston, United States
HQ citystring
Holliston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
concussion diagnostics, brain health assessment, VR eye tracking, neurological biomarkers, digital neurotechnology
Industry3 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Neurological Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Sales
TypeHardware Sales
Description

Sale of EYE-SYNC system including VR headset (Pico Neo 3 Pro Eye), Samsung tablet, carrying case, and customizable battery. Pricing not publicly disclosed, requires contact for quote.

neurosync.health
2Software/Subscription
TypeSubscription Recurring
Description

Software licensing for proprietary eye tracking analytics and assessment battery. Includes secure, HIPAA compliant cloud data storage.

neurosync.health
3Training and Certification
TypeProfessional Services
Description

Initial training and onboarding for providers on platform use, administration, and result interpretation. Certification provided upon completion.

neurosync.health
4Clinical Trial Services
TypeProfessional Services
Description

CNS drug trials support with quantifiable biomarkers for pharmaceutical companies, working as both CRO and technology provider.

neurosync.health
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1EYE-SYNC Complete System
ModelHybridBilling cadenceMulti-year contract
Notes

Complete package includes VR headset (Pico Neo 3 Eye), Android tablet, protective case, customizable battery, EMR integration, HIPAA compliant storage. Price not publicly disclosed - requires contact for quote.

neurosync.health
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1EYE-SYNC
Description

FDA-cleared virtual reality eye-tracking headset and assessment platform for concussion diagnosis and brain health evaluation.

neurosync.health
+2 more records
Core offering1 text field

NeuroSync provides a digital health platform that assesses brain health through VR-based eye tracking technology. The core offering is EYE-SYNC, an FDA-cleared system combining a wireless VR headset with proprietary analytics software to record and analyze eye movements as an aid to concussion diagnosis and visual impairment identification, completing assessments in under 60 seconds. A secondary offering, PRO-SYNC, delivers brain performance monitoring via a mobile application that scores sleep quality and mental acuity for readiness and performance optimization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 0.9 test-retest reliability
+3 more records
Product overview1 text field

NeuroSync offers a platform of brain health assessment and performance optimization products centered around its FDA-cleared EYE-SYNC VR-based eye tracking system. EYE-SYNC serves as the core clinical product for concussion diagnosis and visual impairment assessment, while PRO-SYNC extends reach to consumer brain performance monitoring via mobile app. The platform integrates hardware (VR headset and tablet), proprietary analytics software, customizable reporting, and EMR/API connectivity into a unified solution for healthcare, sports, military, and biopharma markets.

Product and service3 records
1EYE-SYNC
CategoryNeurological Diagnostics
Description

FDA-cleared VR-based eye tracking platform for concussion diagnosis and visual impairment identification. Uses proprietary algorithms to record, analyze, and quantify eye movements as an aid to concussion diagnosis. Assessments complete in under 60 seconds and provide actionable, objective data to clinicians. Targeted at healthcare providers, sports organizations, military, and biopharma clients.

2PRO-SYNC
CategoryBrain Performance Monitoring
Description

Mobile brain performance monitoring application for sleep quality and mental acuity assessment. Screens timing, working memory, attention, inhibitory control, and concentration in under 60 seconds per assessment. Provides 1-100 readiness scores and trend monitoring. General wellness product, not FDA cleared as a medical device.

3EYE-SYNC Hardware Package
CategoryHardware Bundle
Description

Complete hardware bundle including Pico Neo 3 Eye wireless VR headset, Samsung S10 Android Tablet, protective carrying case, customizable battery, EMR integration, and HIPAA-compliant cloud storage. Wireless, Bluetooth-enabled system for portable patient assessments sold as part of the EYE-SYNC complete system.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Pico Interactive
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-04-05
Description

Pico Interactive provides the Neo 3 Pro Eye VR headset integrated with NeuroSync's EYE-SYNC technology. This partnership enables the wireless, Bluetooth-enabled VR platform for eye tracking assessments. The partnership was formed in 2021 and represents the third generation of hardware integration.

neurosync.health
Strategic tierCoreTypeTechnology or Integration
Description

Tobii provides eye tracking technology and Tobii Ocumen middleware for the EYE-SYNC platform. Tobii's high-level filters process raw eye tracking data into reliable biomarkers, enabling NeuroSync's analysis. This partnership dates to the third generation EYE-SYNC launch in 2020-2021.

Strategic tierSecondaryTypeTechnology or Integration
Description

NeuroSync is expanding its working relationship with Magic Leap for AR technology. The partnership is expected to enable additional product solutions in the AR space. Expanded partnership announced in late 2021.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

ImPACT Applications is the established incumbent in concussion baseline and post-injury testing, used across professional and collegiate sports. While its core modality is neurocognitive testing rather than eye-tracking, it competes for the same sports medicine and clinical concussion assessment budgets.

TypeDirect peer
Description

C3 Logix delivers a multi-modal concussion assessment platform combining balance, cognitive, and visual tracking. It targets the same healthcare and sports customers as NeuroSync with comparable objective concussion evaluation capabilities.

TypeEmerging player
Description

MindMaze combines VR, AI, and neuroscience for neurological assessment and rehabilitation across stroke, TBI, and other indications. It is an emerging player that overlaps with NeuroSync in VR-based brain health, particularly in rehabilitation and performance use cases.

TypeDirect peer
Description

HeadCheck Health offers a concussion management platform for sports organizations, integrating symptom evaluation, balance, and cognitive testing. It competes with NeuroSync for sports medicine and athletic training room deployments.

TypeDirect peer
Description

RightEye uses eye-tracking technology to assess brain and visual health, including concussion and neurological conditions. It is the closest direct competitor to NeuroSync's EYE-SYNC, serving similar clinical and sports customers with objective eye-movement biomarkers.

TypeBroad incumbent
Description

Posit Science develops computerized cognitive training and assessment tools (BrainHQ) used in clinical research and brain performance. It is a broader incumbent in digital brain health with overlapping cognitive assessment capabilities, though without NeuroSync's hardware-based eye-tracking modality.

TypeDirect peer
Description

Oculogica develops the EyeBOX, an FDA-cleared eye-tracking device for concussion and traumatic brain injury assessment. It competes head-to-head with EYE-SYNC in objective concussion diagnostics for clinicians and sports programs.

TypeDirect peer
Description

Sway Medical provides mobile-based balance and cognitive assessment tools widely used in concussion management across collegiate and professional sports. It is a directly comparable, technology-driven concussion assessment solution targeting similar sports medicine customers.

TypeEmerging player
Description

Cambridge Brain Sciences provides digital cognitive assessment tools used in clinical research, healthcare, and consumer wellness. It is an emerging player in objective brain health measurement, partially overlapping with PRO-SYNC's cognitive monitoring use cases.

TypeOthers
Description

While primarily an ophthalmic pharmaceutical company, NovaBay is referenced as a peripheral adjacency because of NeuroSync's vision/eye-tracking focus and the overlap between neuro-ophthalmic diagnostics and broader eye health markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroSync

Digital Neurological Diagnosticsneurosync.health

NeuroSync develops an FDA-cleared, VR-based eye tracking platform that uses proprietary algorithms to assess brain health and diagnose concussion, serving healthcare providers, sports organizations, military, and biopharma customers across the US and EU.

What NeuroSync does

NeuroSync, Inc. (formerly SyncThink) is a privately held digital health company founded in 2015 by neurosurgeon Dr. Jam Ghajar, headquartered in Holliston, Massachusetts with additional offices in Boston and a technology presence in Palo Alto. The company develops a VR-based eye tracking platform that uses proprietary algorithms — developed over more than 15 years of clinical research and protected by 16 patents — to record, analyze, and quantify eye movement patterns as objective biomarkers for neurological conditions, most notably concussion. Its flagship product, EYE-SYNC, is an FDA-cleared (510(k) 2016, Breakthrough Device Designation 2019, concussion diagnosis clearance 2021), CE Mark-certified (2022) wireless VR system that completes assessments in under 60 seconds, integrates with EMR systems via REST API, and stores data in HIPAA-compliant cloud infrastructure. PRO-SYNC, launched in 2022, extends the underlying technology into consumer brain performance and wellness monitoring via a mobile app, while the NeuroSync Management Portal (October 2023) provides a web-based administrative layer for provider workflows.

The company sells EYE-SYNC as a bundled hardware-plus-software solution (Pico Neo 3 Pro Eye VR headset, Samsung tablet, proprietary analytics software, EMR integration) under multi-year enterprise contracts with quote-based pricing, supplemented by provider training and certification, clinical trial services for CNS drug development, and recurring software/cloud subscription. Go-to-market is enterprise field sales targeting four primary verticals: healthcare providers (hospitals and clinics such as Massachusetts General Hospital, Texas Medical Center, Houston Methodist, Sutter Health, and Barnabas Health), collegiate and professional sports organizations (Rice University, Georgia Tech, Virginia Tech), military and Department of Defense buyers, and biopharma companies running CNS clinical trials. The platform has been deployed to 5,188 clinicians and used for 405,000 patient assessments, generating a proprietary dataset of over 1.57 billion data points. Distribution is enabled through hardware partnerships with Pico Interactive and Tobii, with an expanding relationship with Magic Leap for future AR-based product development. The company is led by Chairman, CEO and President Gary L. Gregory, who has led multiple healthcare startups including an IPO at NeuroMetrix. In May 2025, the FDA's Center for Devices and Radiological Health issued a warning letter to NeuroSync for design control failures on the EYE-SYNC device.

NeuroSync firmographics

Firmographics
Name
NeuroSync
Legal name
NeuroSync Inc.
Website
https://neurosync.health
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuroSync develops an FDA-cleared, VR-based eye tracking platform that uses proprietary algorithms to assess brain health and diagnose concussion, serving healthcare providers, sports organizations, military, and biopharma customers across the US and EU.
Ownership category
akta.pro rank

NeuroSync industry classification

Industry
Product category
Digital Neurological Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Concussion diagnostics
  • Brain health assessment
  • VR eye tracking
  • Neurological biomarkers
  • Digital neurotechnology

Where NeuroSync is headquartered

Location

Headquarters

HQ city
Holliston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

NeuroSync business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Hardware Sales: Sale of EYE-SYNC system including VR headset (Pico Neo 3 Pro Eye), Samsung tablet, carrying case, and customizable battery. Pricing not publicly disclosed, requires contact for quote.
  2. Software/Subscription: Software licensing for proprietary eye tracking analytics and assessment battery. Includes secure, HIPAA compliant cloud data storage.
  3. Training and Certification: Initial training and onboarding for providers on platform use, administration, and result interpretation. Certification provided upon completion.
  4. Clinical Trial Services: CNS drug trials support with quantifiable biomarkers for pharmaceutical companies, working as both CRO and technology provider.

Pricing tiers

ModelBillingPrice
HybridMulti-year contractEYE-SYNC Complete System

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

NeuroSync product offering

Product offering

Core offering

NeuroSync provides a digital health platform that assesses brain health through VR-based eye tracking technology. The core offering is EYE-SYNC, an FDA-cleared system combining a wireless VR headset with proprietary analytics software to record and analyze eye movements as an aid to concussion diagnosis and visual impairment identification, completing assessments in under 60 seconds. A secondary offering, PRO-SYNC, delivers brain performance monitoring via a mobile application that scores sleep quality and mental acuity for readiness and performance optimization.

Product overview

NeuroSync offers a platform of brain health assessment and performance optimization products centered around its FDA-cleared EYE-SYNC VR-based eye tracking system. EYE-SYNC serves as the core clinical product for concussion diagnosis and visual impairment assessment, while PRO-SYNC extends reach to consumer brain performance monitoring via mobile app. The platform integrates hardware (VR headset and tablet), proprietary analytics software, customizable reporting, and EMR/API connectivity into a unified solution for healthcare, sports, military, and biopharma markets.

Differentiator

Problem solved

Functional benefit

Brands

  • EYE-SYNC: FDA-cleared virtual reality eye-tracking headset and assessment platform for concussion diagnosis and brain health evaluation.
  • PRO-SYNC
  • NeuroSync Management Portal

Products and services

  • EYE-SYNC FDA-cleared VR-based eye tracking platform for concussion diagnosis and visual impairment identification. Uses proprietary algorithms to record, analyze, and quantify eye movements as an aid to concussion diagnosis. Assessments complete in under 60 seconds and provide actionable, objective data to clinicians. Targeted at healthcare providers, sports organizations, military, and biopharma clients.
  • PRO-SYNC Mobile brain performance monitoring application for sleep quality and mental acuity assessment. Screens timing, working memory, attention, inhibitory control, and concentration in under 60 seconds per assessment. Provides 1-100 readiness scores and trend monitoring. General wellness product, not FDA cleared as a medical device.
  • EYE-SYNC Hardware Package Complete hardware bundle including Pico Neo 3 Eye wireless VR headset, Samsung S10 Android Tablet, protective carrying case, customizable battery, EMR integration, and HIPAA-compliant cloud storage. Wireless, Bluetooth-enabled system for portable patient assessments sold as part of the EYE-SYNC complete system.

Quantifiable outcome

  • 0.9 test-retest reliability
  • +3 more outcomes

Companies that use NeuroSync

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles4 records

NeuroSync technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature8 records

NeuroSync partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and secondary.

  • Pico InteractivecoreTechnology or Integration · 5 April 2021Pico Interactive provides the Neo 3 Pro Eye VR headset integrated with NeuroSync's EYE-SYNC technology. This partnership enables the wireless, Bluetooth-enabled VR platform for eye tracking assessments. The partnership was formed in 2021 and represents the third generation of hardware integration.
  • TobiicoreTechnology or IntegrationTobii provides eye tracking technology and Tobii Ocumen middleware for the EYE-SYNC platform. Tobii's high-level filters process raw eye tracking data into reliable biomarkers, enabling NeuroSync's analysis. This partnership dates to the third generation EYE-SYNC launch in 2020-2021.
  • Magic LeapsecondaryTechnology or IntegrationNeuroSync is expanding its working relationship with Magic Leap for AR technology. The partnership is expected to enable additional product solutions in the AR space. Expanded partnership announced in late 2021.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

NeuroSync competitors and assessment

Company assessment

Broad incumbents

  • ImPACT Applications: ImPACT Applications is the established incumbent in concussion baseline and post-injury testing, used across professional and collegiate sports. While its core modality is neurocognitive testing rather than eye-tracking, it competes for the same sports medicine and clinical concussion assessment budgets.
  • Posit Science: Posit Science develops computerized cognitive training and assessment tools (BrainHQ) used in clinical research and brain performance. It is a broader incumbent in digital brain health with overlapping cognitive assessment capabilities, though without NeuroSync's hardware-based eye-tracking modality.

Direct peers

  • C3 Logix: C3 Logix delivers a multi-modal concussion assessment platform combining balance, cognitive, and visual tracking. It targets the same healthcare and sports customers as NeuroSync with comparable objective concussion evaluation capabilities.
  • HeadCheck Health: HeadCheck Health offers a concussion management platform for sports organizations, integrating symptom evaluation, balance, and cognitive testing. It competes with NeuroSync for sports medicine and athletic training room deployments.
  • RightEye: RightEye uses eye-tracking technology to assess brain and visual health, including concussion and neurological conditions. It is the closest direct competitor to NeuroSync's EYE-SYNC, serving similar clinical and sports customers with objective eye-movement biomarkers.
  • Oculogica: Oculogica develops the EyeBOX, an FDA-cleared eye-tracking device for concussion and traumatic brain injury assessment. It competes head-to-head with EYE-SYNC in objective concussion diagnostics for clinicians and sports programs.
  • Sway Medical: Sway Medical provides mobile-based balance and cognitive assessment tools widely used in concussion management across collegiate and professional sports. It is a directly comparable, technology-driven concussion assessment solution targeting similar sports medicine customers.

Emerging players

  • MindMaze: MindMaze combines VR, AI, and neuroscience for neurological assessment and rehabilitation across stroke, TBI, and other indications. It is an emerging player that overlaps with NeuroSync in VR-based brain health, particularly in rehabilitation and performance use cases.
  • Cambridge Brain Sciences: Cambridge Brain Sciences provides digital cognitive assessment tools used in clinical research, healthcare, and consumer wellness. It is an emerging player in objective brain health measurement, partially overlapping with PRO-SYNC's cognitive monitoring use cases.

Others

  • NovaBay Pharmaceuticals: While primarily an ophthalmic pharmaceutical company, NovaBay is referenced as a peripheral adjacency because of NeuroSync's vision/eye-tracking focus and the overlap between neuro-ophthalmic diagnostics and broader eye health markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroSync social profiles

Digital presence

NeuroSync compliance and trust

Trust signal

Compliance3 records

NeuroSync financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroSync leadership team

Management profile

Number of profiles

Profiles6 records

NeuroSync funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroSync M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroSync

What does NeuroSync do?

NeuroSync provides a digital health platform that assesses brain health through VR-based eye tracking technology. The core offering is EYE-SYNC, an FDA-cleared system combining a wireless VR headset with proprietary analytics software to record and analyze eye movements as an aid to concussion diagnosis and visual impairment identification, completing assessments in under 60 seconds. A secondary offering, PRO-SYNC, delivers brain performance monitoring via a mobile application that scores sleep quality and mental acuity for readiness and performance optimization.

Is NeuroSync a public or private company?

NeuroSync is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuroSync founded?

NeuroSync was founded in 2015. It employs 11 to 50 people.

Where is NeuroSync based?

NeuroSync is headquartered in Holliston, United States, in the North America region.

How does NeuroSync make money?

Four revenue lines are on record. Hardware Sales are the primary driver. The others are software/Subscription, training and Certification and clinical Trial Services.

Who are NeuroSync's main competitors?

Broad incumbents on record are ImPACT Applications and Posit Science. Direct peers are C3 Logix, HeadCheck Health, RightEye, Oculogica and Sway Medical. Emerging players are MindMaze and Cambridge Brain Sciences. NovaBay Pharmaceuticals is listed as an others.

Does NeuroSync have an API?

Yes. NeuroSync offers a REST API for data export to EMR systems and other databases. The API enables secure data transfer of assessment results to Electronic Medical Records or athlete management systems. Results can also be exported via PDF through the API. The API is included with the product package and supports HIPAA-compliant cloud storage.

What industry is NeuroSync in?

NeuroSync's product category is Digital Neurological Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Community Impact5 new businesses open in Grapevine, Colleyville and SouthlakeFive new businesses opened in Grapevine, Colleyville, and Southlake, including Flip Flop Shops, Bucketheads, Moda, Game Show Studio, and NeuroSync Diagnostics. The openings span footwear, clothing, entertainment, and medical diagnostics, with some offering remote EEG services.Community ImpactNeuroSync Diagnostics opens as sister business to A&B Neurology in ColleyvilleNeuroSync Diagnostics opened in Colleyville to provide remote brain scanning and monitoring for A&B Neurology. Founder Dr. Babak Rezaei said the in-house service improves patient care by avoiding outsourcing. Remote EEG testing uses electrodes for 48-96 hours to record brain data across environments.RapsFDA warns four device makers over lax processesThe FDA's Center for Devices and Radiological Health issued warning letters to four medical device manufacturers in May 2025 for various regulatory violations discovered during inspections. Kabe Labortechnik of Germany was cited for unvalidated manufacturing processes and software for its SAFE-T-FILL capillary blood collection systems, with the agency refusing entry of devices into the US until violations are addressed. NeuroSync of Massachusetts received a warning for design control failures with its EYE-SYNC virtual reality eye-tracking headset, while Microspecialties of Connecticut was cited for sterilization process shortfalls that led to product recalls. United Health Products of New Jersey was warned for conducting a clinical study on hemostatic products without obtaining the required investigational device exemption approval.The VergeA neurotech company wants to use eye tracking to prevent injuriesNeuroSync is launching Pro-Sync, a new VR-based eye-tracking platform designed to assess athlete cognitive performance and detect fatigue to help prevent sports injuries. The system utilizes wireless headsets to monitor eye movements, building on the company's previous FDA-cleared concussion testing technology and internal research from partnerships with teams like the Golden State Warriors and Stanford University. While the company aims to streamline injury prevention through this tool, some medical experts remain skeptical about the validity of measuring 'cognitive fatigue' via voluntary tasks.